Form 4: Roivant Director Receives Equity Awards, Settles Taxes

Roivant Sciences Ltd. director Meghan Fitzgerald was granted 14,524 restricted stock units and 33,726 stock options, while also disposing of 937 shares for tax obligations.

Summary

• Director Meghan Fitzgerald was granted 14,524 restricted stock units (RSUs) on September 10, 2025, as an annual award under the Company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.
• These RSUs are scheduled to vest 100% on September 10, 2026, contingent upon continuous service through that date.
• Fitzgerald also received an annual award of 33,726 stock options to purchase Common Shares on September 10, 2025, with an exercise price of $13.77 and an expiration date of September 9, 2035.
• These stock options are scheduled to vest and become exercisable 100% on September 10, 2026, subject to continuous service.
• Concurrently, 937 Common Shares were disposed of through a 'net settlement' at a price of $13.77 per share to satisfy applicable tax withholding obligations related to the vesting and settlement of previous awards.
• Following these reported transactions, Fitzgerald beneficially owns 42,963 Common Shares directly and 33,726 stock options directly.

Sentiment

Score: 7

Explanation: The filing reflects routine, positive compensation events for a director, aligning their interests with shareholders, offset slightly by a small share disposal for tax purposes. It indicates stable corporate governance practices regarding director compensation.

Positives

• The grant of 14,524 restricted stock units (RSUs) to a director aligns management incentives with long-term shareholder interests.
• The award of 33,726 stock options with an exercise price of $13.77 provides a long-term incentive for the director, linking compensation to future stock performance.
• These awards are part of a structured Non-Employee Director Compensation Policy and the 2021 Equity Incentive Plan, indicating a formal and transparent approach to corporate governance and compensation.

Negatives

• The disposal of 937 Common Shares at $13.77 per share for tax withholding purposes results in a slight reduction in the director's direct shareholding.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon the reporting person's continuous service through September 10, 2026, meaning the awards could be forfeited if service ceases before this date.

Future Outlook

The director's equity awards (RSUs and stock options) are scheduled to vest 100% on September 10, 2026, contingent upon continuous service, indicating a future incentive alignment for the director.

Management Comments

• The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.
• The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

Industry Context

The granting of equity awards, such as restricted stock units and stock options, to non-employee directors is a standard compensation practice across many industries, particularly in the biotechnology and pharmaceutical sectors like Roivant Sciences. This approach is widely adopted to attract and retain qualified board members, align their long-term interests with shareholder value creation, and provide performance-based compensation. The net settlement of shares for tax withholding is also a common and efficient mechanism for managing equity compensation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for non-employee director compensation is a common practice, comparable to compensation structures seen in peer companies within the biotechnology sector, such as Moderna or Regeneron, which often utilize a mix of cash and equity.
• The one-year vesting schedule (September 2025 to September 2026) for these annual equity awards is typical for director grants, ensuring continued engagement and alignment with company performance.
• The net settlement of shares to cover tax obligations upon vesting is a standard and efficient method for directors to manage their tax liabilities without needing to sell additional shares on the open market, a practice observed across most publicly traded companies offering equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards align the director's long-term interests with shareholder value creation, potentially leading to more focused governance. The small disposal for tax is a minor, routine event.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued service of Meghan Fitzgerald through September 10, 2026, for the vesting of RSUs and stock options.
• Vesting of 14,524 restricted stock units on September 10, 2026.
• Vesting and exercisability of 33,726 stock options on September 10, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a non-employee director and a standard tax-related share disposal. It does not contain information that would fundamentally alter the investment thesis for Roivant Sciences. The awards align director incentives with long-term shareholder value, which is a positive for governance, but the overall impact on the company's financial performance or strategic direction is neutral. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a strong catalyst for a buy or sell decision.

Keywords

Roivant Sciences, ROIV, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Incentive Plan, Share Disposal, Tax Withholding